Aytu Biopharma, Inc (AYTU): Cash & Equivalents
$26.31M
As of 2026-06-30
+4.6%
3-year compound annual growth
-11.9%
5-year compound annual growth
+12.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $26.31M | -15.0% | 2026-09-22, Balance as of period end |
| 2025-06-30 | $30.95M | +54.7% | 2026-09-22, Balance as of period end |
| 2024-06-30 | $20.01M | -13.0% | 2025-09-23, Balance as of period end |
| 2023-06-30 | $22.98M | +18.7% | 2024-09-26, Balance as of period end |
| 2022-06-30 | $19.36M | -61.0% | 2023-10-12, Balance as of period end |
| 2021-06-30 | $49.65M | +3.3% | 2022-09-27, Balance as of period end |
| 2020-06-30 | $48.08M | +335.4% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $11.04M | +57.5% | 2020-10-06, Balance as of period end |
| 2018-06-30 | $7.01M | +774.0% | 2019-09-26, Balance as of period end |
| 2017-06-30 | $802.3K | -90.0% | 2018-09-06, Balance as of period end |
| 2016-06-30 | $8.05M | +9.5% | 2017-08-31, Balance as of period end |
| 2015-06-30 | $7.35M | +178.6% | 2016-09-01, Balance as of period end |
| 2014-06-30 | $2.64M | n/a | 2015-09-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $26.31M | -15.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $24.09M | +18.6% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $89.13M | +16.9% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
Compare AYTU, NKTR, DERM, AGIO side by side · Screen every company in Pharmaceutical Preparations ↗